The structure of the Medicare Part D program produces interesting, and sometimes counterintuitive, financial outcomes when drug list prices are decreased and rebates are eliminated. This paper analyzes the impact of mid-year drug list price reductions coupled with a reduction in rebates resulting in identical net price.